CRHR2

Across TCGA pan-cancer cohorts, CRHR2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CRHR2 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher CRHR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRHR2 expression acts as an unfavorable survival marker.

LGG, LIHC, and PRAD are the cancer types where CRHR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.228	0.812	<.001	12	view →
LIHC	DFS	Median	All	0.102	0.555	.003	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.200	0.611	.033	3	view →
SKCM	OS	Median	All	0.714	0.871	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CRHR2–LGG (OS)

Open the LGG breakdown →